Roivant Sciences Ltd.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Lisa C. McClainHouse · R · MI |
ROIVRoivant Sciences Ltd. · Stock |
Sale $1,001 - $15,000 |
Nov 21, 2025 | Oct 30, 2025 | Filing ↗ |
Lisa C. McClainHouse · R · MI |
ROIVRoivant Sciences Ltd. · Stock |
Purchase $1,001 - $15,000 |
Nov 21, 2025 | Oct 30, 2025 | Filing ↗ |
Lisa C. McClainHouse · R · MI |
ROIVRoivant Sciences Ltd. · Stock |
Sale $1,001 - $15,000 |
Nov 21, 2025 | Oct 31, 2025 | Filing ↗ |
Lisa C. McClainHouse · R · MI |
ROIVRoivant Sciences Ltd. · Stock |
Purchase $1,001 - $15,000 |
Aug 13, 2025 | Jun 17, 2025 | Filing ↗ |
Whale Activity
- Increased224
- New98
- Held51
- Decreased128
- Closed67
- No prior filing22
| Filer | Shares | Value | Change |
|---|---|---|---|
| FMR LLC | 85.6M | $3.13B | increased |
| BlackRock, Inc. | 61.9M | $2.26B | increased |
| MORGAN STANLEY | 38.6M | $1.41B | decreased |
| QVT Financial LP | 23.7M | $867.6M | held |
| VANGUARD CAPITAL MANAGEMENT LLC | 23.1M | $845.8M | increased |
| STATE STREET CORP | 22.4M | $819.2M | increased |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 21.7M | $795.2M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 21.7M | $792.0M | increased |
| UBS Group AG | 13.9M | $509.4M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 12.5M | $468.0M | increased |
| JENNISON ASSOCIATES LLC | 12.1M | $441.3M | increased |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 11.0M | $402.3M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| MANCHESTER KEITH SDirector · Director | Sale | −798 | $38.24 | $31K | Nov 17, 2026 | Form 4 ↗ |
| MANCHESTER KEITH SDirector · Director | Sale | −75.7K | $38.24 | $2.9M | Nov 17, 2026 | Form 4 ↗ |
| MANCHESTER KEITH SDirector · Director | Sale | −525.5K | $38.24 | $20.1M | Nov 17, 2026 | Form 4 ↗ |
| MANCHESTER KEITH SDirector · Director | Sale | −79.5K | $39.17 | $3.1M | Nov 16, 2026 | Form 4 ↗ |
| MANCHESTER KEITH SDirector · Director | Sale | −550.3K | $39.17 | $21.6M | Nov 16, 2026 | Form 4 ↗ |
| MANCHESTER KEITH SDirector · Director | Sale | −18.9K | $38.99 | $738K | Nov 16, 2026 | Form 4 ↗ |
| MANCHESTER KEITH SDirector · Director | Sale | −131.1K | $38.99 | $5.1M | Nov 16, 2026 | Form 4 ↗ |
| Pulik RichardCFO | Sale | −82.2K | $42.03 | $3.5M | Nov 11, 2026 | Form 4 ↗ |
| Pulik RichardCFO | Sale | −47.6K | $41.89 | $2.0M | Nov 11, 2026 | Form 4 ↗ |
| Pulik RichardCFO | Sale | −45.2K | $41.47 | $1.9M | Nov 11, 2026 | Form 4 ↗ |
| Pulik RichardCFO | Sale | −125.0K | $41.20 | $5.2M | Nov 10, 2026 | Form 4 ↗ |
| Venker EricPresident & Immunovant CEO | Sale | −29.7K | $41.00 | $1.2M | Nov 10, 2026 | Form 4 ↗ |
| Venker EricPresident & Immunovant CEO | Sale | −158.2K | $40.44 | $6.4M | Nov 10, 2026 | Form 4 ↗ |
| Venker EricPresident & Immunovant CEO | Sale | −200.0K | $36.31 | $7.3M | Nov 3, 2026 | Form 4 ↗ |
| Venker EricPresident & Immunovant CEO | Sale | −200.0K | $36.59 | $7.3M | Oct 28, 2026 | Form 4 ↗ |
| Venker EricPresident & Immunovant CEO | Sale | −185.9K | $35.09 | $6.5M | Oct 20, 2026 | Form 4 ↗ |
| Venker EricPresident & Immunovant CEO | Sale | −14.1K | $35.42 | $501K | Oct 20, 2026 | Form 4 ↗ |
| Epperly Melissa B,Director · Director | Sale | −900 | $36.57 | $33K | Oct 1, 2026 | Form 4 ↗ |
| Epperly Melissa B,Director · Director | Sale | −16.9K | $36.08 | $608K | Oct 1, 2026 | Form 4 ↗ |
| Venker EricPresident & Immunovant CEO | Sale | −200.0K | $36.62 | $7.3M | Sep 30, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 16.0M | $565.8M | 0.02% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 11.5M | $408.6M | 0.22% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 6.7M | $235.6M | 0.50% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 5.2M | $182.9M | 0.19% | Jun 30, 2026 |
| Invesco S&P MidCap Momentum ETF Invesco Exchange-Traded Fund Trust | 5.2M | $177.0M | 2.47% | Jul 31, 2026 |
| VANGUARD EXPLORER FUND | 3.0M | $100.7M | 0.46% | Jul 31, 2026 |
| VANGUARD HEALTH CARE INDEX FUND VANGUARD WORLD FUND | 1.4M | $49.2M | 0.22% | Aug 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF Dimensional ETF Trust | 1.2M | $39.5M | 0.08% | Jul 31, 2026 |
| iShares Russell 1000 Value ETF iShares Trust | 1.1M | $38.7M | 0.05% | Jun 30, 2026 |
| VANGUARD S&P MID-CAP 400 INDEX FUND VANGUARD ADMIRAL FUNDS | 741.7K | $25.7M | 0.44% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list ROIV's shares (CUSIP G76279101), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 85.6M shares11.8%
Nov 5, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 85.6M shares11.8%
Nov 5, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 59.3M shares8.2%
Oct 27, 2026 · ↗ - Morgan Stanley Investment Management Inc.SCHEDULE 13G/A · passive (13G) · 39.4M shares5.5%
Aug 13, 2026 · ↗ - Morgan StanleySCHEDULE 13G/A · passive (13G) · 40.7M shares5.7%
Aug 13, 2026 · ↗ - Morgan Stanley Investment Management Inc.SCHEDULE 13G/A · passive (13G) · 48.3M shares6.7%
May 12, 2026 · ↗ - Morgan StanleySCHEDULE 13G/A · passive (13G) · 49.5M shares6.9%
May 12, 2026 · ↗ - Ramaswamy VivekSCHEDULE 13G/A · passive (13G) · 25.5M shares3.6%
May 6, 2026 · ↗ - Morgan Stanley Investment Management Inc.SCHEDULE 13G/A · passive (13G) · 54.4M shares7.8%
Feb 11, 2026 · ↗ - Morgan StanleySCHEDULE 13G/A · passive (13G) · 55.5M shares8.0%
Feb 11, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming Roivant Sciences Ltd. as the client.
- THE CONAFAY GROUP, LLCROIVANT SCIENCES, INC. · 2022 Q1—
Filing ↗ - THE CONAFAY GROUP, LLCROIVANT SCIENCES, INC. · 2021 Q4 · BUD, MED$20K
Filing ↗ - THE CONAFAY GROUP, LLCROIVANT SCIENCES, INC. · 2021 Q3 · BUD, MED$20K
Filing ↗ - BAKER DONELSON BEARMAN CALDWELL & BERKOWITZROIVANT SCIENCES, INC. · 2021 Q2—
Filing ↗ - THE CONAFAY GROUP, LLCROIVANT SCIENCES, INC. · 2021 Q2 · MED, BUD$20K
Filing ↗
Government Contracts
No federal contract awards found for Roivant Sciences Ltd..
U.S. Patents
No USPTO patent applications found for Roivant Sciences Ltd..
Annual Financials
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $8.3M | $29.1M | $32.7M | $31.5M | $55.3M |
| Operating income | -$515.1M | -$1.00B | $4.50B | -$906.8M | -$1.35B |
| Net income | -$299.8M | -$172.0M | $4.35B | -$1.01B | -$845.3M |
| Diluted EPS | -$0.54 | -$0.24 | $5.23 | -$1.42 | -$1.26 |
| Operating cash flow | -$750.3M | -$839.5M | -$765.3M | -$843.4M | -$677.7M |
| Cash and equivalents | $1.42B | $2.72B | $6.49B | $1.68B | $2.06B |
| Total assets | $5.71B | $5.44B | $7.22B | $2.39B | $2.59B |
| Total liabilities | $416.3M | $249.7M | $774.0M | $782.0M | $523.7M |
| Shareholders' equity | $4.53B | $4.69B | $5.97B | $1.16B | $1.66B |
As Roivant Sciences Ltd. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed May 20, 2026 ↗
Stock Splits
No stock splits in ROIV's price history.
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 9, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureOct 21, 2026
EDGAR ↗ - 8-K · Items 5.07, 9.01Shareholder voteSep 18, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureSep 8, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsAug 28, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureAug 27, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 20, 2026
EDGAR ↗

